Biotech companies at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
57 biotech companies are at ASCO 2027 — 57 with a booth in the exhibit hall. 57 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–19 of 57 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
Accord BioPharma Raleigh, NC | |
Specialty arm of the Intas group marketing the prostate cancer drug Camcevi, lenalidomide, and supportive-care biosimilars such as filgrastim and pegfilgrastim. | Booth Exhibiting at Booth 37073 |
Acrotech Biopharma East Windsor, NJ | |
Specialty drug company commercializing approved cancer medicines in the US, including treatments for T-cell lymphoma. | Booth Exhibiting at Booth 10092 |
Akeso Zhongshan City, China | |
Chinese antibody drugmaker with bispecific immunotherapies, including the PD-1/VEGF antibody ivonescimab for lung cancer. | Booth Exhibiting at Booth 37147 |
ALX Oncology South San Francisco, CA | |
Clinical-stage immuno-oncology biotech developing evorpacept, a CD47 blocker, with positive data in HER2-positive gastric cancer. | Booth Exhibiting at Booth IH09 |
Arcus Biosciences Hayward, CA | |
Clinical-stage biotech with registrational programs in kidney cancer (HIF-2α inhibitor casdatifan) and pancreatic cancer (CD73 inhibitor quemliclustat). | Booth Exhibiting at Booth 32146 |
Ascentage Pharma Suzhou, China | |
Drug developer focused on blood cancers, with the TKI olverembatinib and the Bcl-2 inhibitor lisaftoclax among its programs. | Booth Exhibiting at Booth 37103 |
AVEO Oncology Boston, MA | |
Oncology company, owned by LG Chem, that markets the kidney cancer drug tivozanib (Fotivda) in the US. | Booth Exhibiting at Booth 19023 |
BioNTech Mainz, Germany | |
Immunotherapy company developing mRNA cancer vaccines, a PD-L1/VEGF bispecific antibody, antibody-drug conjugates and CAR-T cell therapies. | Booth Exhibiting at Booth 24103 |
Celcuity Minneapolis, MN | |
Clinical-stage biotech developing gedatolisib, a PI3K/mTOR pathway inhibitor in Phase 3 for HR-positive, HER2-negative advanced breast cancer. | Booth Exhibiting at Booth 15149, 16151 |
Cogent Biosciences Waltham, MA | |
Biotech preparing to launch the KIT inhibitor bezuclastinib for systemic mastocytosis and gastrointestinal stromal tumors. | Booth Exhibiting at Booth 26149 |
Coherus Oncology Redwood City, CA | |
Immuno-oncology company marketing the PD-1 antibody toripalimab (Loqtorzi) for nasopharyngeal cancer and developing further immunotherapies. | Booth Exhibiting at Booth 10095 |
Corcept Therapeutics Redwood City, CA | |
Developer of selective cortisol modulators, testing relacorilant in platinum-resistant ovarian cancer alongside hypercortisolism treatments. | Booth Exhibiting at Booth 27153 |
Curium Saint Louis, MO | |
Nuclear medicine company manufacturing SPECT and PET imaging agents and therapeutic radiopharmaceuticals in Europe and the US. | Booth Exhibiting at Booth 33155 |
Deciphera Pharmaceuticals Waltham, MA | |
Ono Pharmaceutical company marketing kinase inhibitors for gastrointestinal stromal tumors and tenosynovial giant cell tumor. | Booth Exhibiting at Booth 14131 |
Dendreon Pharmaceuticals Seal Beach, CA | |
Maker of Provenge (sipuleucel-T), an autologous cellular immunotherapy for prostate cancer, and a cell therapy manufacturing services provider. | Booth Exhibiting at Booth 17143 |
Elevar Therapeutics Fort Lee, NJ | |
Oncology biotech developing rivoceranib with camrelizumab as a first-line treatment for liver cancer. | Booth Exhibiting at Booth 34071 |
enGene Boston, MA | |
Clinical-stage company developing non-viral genetic medicines delivered into the bladder, starting with non-muscle invasive bladder cancer. | Booth Exhibiting at Booth 25085 |
Exelixis Alameda, CA | |
Oncology drugmaker whose cabozantinib (Cabometyx) treats kidney, liver and thyroid cancers; developing zanzalintinib and other small molecules. | Booth Exhibiting at Booth 27001 Booth Exhibiting at Booth 27059 · Exelixis Medical Affairs |
Fennec Pharmaceuticals Research Triangle Park, NC | |
Specialty company marketing sodium thiosulfate (Pedmark) to reduce cisplatin-related hearing loss in children with cancer. | Booth Exhibiting at Booth 26167, 27165 |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction